PL3175863T3 - Warianty peptydu natriuretycznego typu C - Google Patents

Warianty peptydu natriuretycznego typu C

Info

Publication number
PL3175863T3
PL3175863T3 PL16192229T PL16192229T PL3175863T3 PL 3175863 T3 PL3175863 T3 PL 3175863T3 PL 16192229 T PL16192229 T PL 16192229T PL 16192229 T PL16192229 T PL 16192229T PL 3175863 T3 PL3175863 T3 PL 3175863T3
Authority
PL
Poland
Prior art keywords
natriuretic peptide
type natriuretic
peptide variants
variants
type
Prior art date
Application number
PL16192229T
Other languages
English (en)
Inventor
Daniel J. Wendt
Mika Aoyagi-Scharber
Shinong Long
Michel Claude Vellard
Sianna Castillo
Augustus O. Okhamafe
Christopher P. Price
Original Assignee
Biomarin Pharmaceutical Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43124672&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3175863(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biomarin Pharmaceutical Inc. filed Critical Biomarin Pharmaceutical Inc.
Publication of PL3175863T3 publication Critical patent/PL3175863T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/105—Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics
    • G01N2800/385—Congenital anomalies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL16192229T 2009-05-20 2010-05-20 Warianty peptydu natriuretycznego typu C PL3175863T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18011209P 2009-05-20 2009-05-20
US25456309P 2009-10-23 2009-10-23
EP10778389.6A EP2432489B1 (en) 2009-05-20 2010-05-20 Variants of c-type natriuretic peptide
PCT/US2010/035586 WO2010135541A2 (en) 2009-05-20 2010-05-20 Variants of c-type natriuretic peptide
EP16192229.9A EP3175863B1 (en) 2009-05-20 2010-05-20 Variants of c-type natriuretic peptide

Publications (1)

Publication Number Publication Date
PL3175863T3 true PL3175863T3 (pl) 2022-03-21

Family

ID=43124672

Family Applications (2)

Application Number Title Priority Date Filing Date
PL16192229T PL3175863T3 (pl) 2009-05-20 2010-05-20 Warianty peptydu natriuretycznego typu C
PL10778389T PL2432489T3 (pl) 2009-05-20 2010-05-20 Warianty peptydu natriuretycznego typu C

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL10778389T PL2432489T3 (pl) 2009-05-20 2010-05-20 Warianty peptydu natriuretycznego typu C

Country Status (28)

Country Link
US (6) US8198242B2 (pl)
EP (5) EP4523749A3 (pl)
JP (1) JP5718909B2 (pl)
KR (5) KR20210027537A (pl)
CN (1) CN102481330B (pl)
AR (1) AR078044A1 (pl)
AU (1) AU2010249802B2 (pl)
BR (2) BRPI1012783B1 (pl)
CA (1) CA2758581C (pl)
CL (1) CL2011002430A1 (pl)
DK (2) DK3175863T3 (pl)
ES (2) ES2608457T3 (pl)
FI (1) FIC20220003I1 (pl)
FR (1) FR22C1004I2 (pl)
HR (2) HRP20161739T1 (pl)
HU (3) HUE032582T2 (pl)
IL (1) IL215287A (pl)
LU (1) LUC00248I2 (pl)
MX (1) MX2011012277A (pl)
NL (1) NL301162I2 (pl)
NO (1) NO2022003I1 (pl)
PE (1) PE20120792A1 (pl)
PL (2) PL3175863T3 (pl)
PT (2) PT3175863T (pl)
RU (1) RU2573911C2 (pl)
TW (1) TWI471137B (pl)
WO (1) WO2010135541A2 (pl)
ZA (1) ZA201107087B (pl)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE055861T2 (hu) 2004-04-21 2021-12-28 Alexion Pharma Inc Csontbejuttató konjugátumok és azok alkalmazási módszere fehérjék csonthoz kötéséhez
PE20120792A1 (es) * 2009-05-20 2012-07-27 Biomarin Pharm Inc Variantes de peptidos natriureticos de tipo c
US20120208756A1 (en) 2009-07-23 2012-08-16 Igisu Co., Ltd Composition for external preparation for skin
RU2502519C2 (ru) 2009-08-27 2013-12-27 Кёко ЭНДО Терапевтическое средство для лечения ринита
BR112012027765A2 (pt) 2010-04-30 2019-09-24 Enobia Pharma Inc métodos, composições e kits para tratamento de distúrbios de mineralização da matriz.
US9266939B2 (en) 2010-12-27 2016-02-23 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof
EP2678002A2 (en) 2011-02-25 2014-01-01 Medtronic, Inc. Therapy for kidney disease and/or heart failure
WO2013016148A2 (en) * 2011-07-27 2013-01-31 Medtronic, Inc. Natriuretic peptide compositions and methods of preparation
US20130244937A1 (en) 2011-09-02 2013-09-19 Nile Therapeutics, Inc. Chimeric natriuretic peptide compositions and methods of preparation
SG11201401605QA (en) 2011-10-19 2014-09-26 Alexion Pharma Holding Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
CN104144943B (zh) * 2011-12-23 2017-05-31 梅约医学教育与研究基金会 评估肾结构改变和结果
CN104379171A (zh) * 2012-04-25 2015-02-25 第一三共株式会社 骨修复促进剂
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2014063102A1 (en) * 2012-10-19 2014-04-24 Cornell University Biomimetic boundary lubricants for articular cartilage
JP6232630B2 (ja) * 2013-03-10 2017-11-22 国立大学法人名古屋大学 骨系統疾患治療薬及びその用途
CN103159847B (zh) * 2013-04-12 2014-05-28 叶亮 一种利钠肽及其基因与用途
EP3659624B1 (en) 2014-01-15 2022-11-16 The U.S.A. as represented by the Secretary, Department of Health and Human Services Cartilage targeting agents and their use
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
CA2967851C (en) 2014-12-05 2024-02-27 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
MY199991A (en) * 2015-01-09 2023-12-02 Ascendis Pharma Growth Disorders As Cnp prodrugs
AU2016211447B2 (en) 2015-01-28 2021-09-23 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
CN114796460A (zh) * 2015-07-30 2022-07-29 生物马林药物股份有限公司 C型利尿钠肽变体在治疗骨骼发育不良中的用途
JP7253220B2 (ja) * 2015-07-31 2023-04-06 株式会社 イギス Ｃｎｐ環状ペプチド並びに該環状ペプチドを含む医薬品、外用剤および化粧料
EP3337894A1 (en) 2015-08-17 2018-06-27 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
JP6868617B2 (ja) 2015-09-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定
US11400140B2 (en) 2015-10-30 2022-08-02 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
CA3007315A1 (en) * 2015-12-08 2017-06-15 Biomarin Pharmaceutical Inc. Use of c-type natriuretic peptide variants to treat osteoarthritis
EP4162955A1 (en) * 2016-01-08 2023-04-12 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with carrier attachment at the ring moiety
US11389511B2 (en) 2016-01-08 2022-07-19 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with reduced side-effects
US11311604B2 (en) * 2016-01-08 2022-04-26 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with low NPR-C binding
NZ743488A (en) * 2016-01-08 2023-02-24 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with low initial npr-b activity
CA3007976C (en) * 2016-01-08 2023-09-26 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with large carrier moieties
US11224661B2 (en) * 2016-01-08 2022-01-18 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with increased NEP stability
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
KR20220162816A (ko) 2016-04-01 2022-12-08 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타아제로 근육 약화의 치료
WO2017173395A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
WO2018011266A1 (en) * 2016-07-13 2018-01-18 Ascendis Pharma A/S Conjugation method for carrier-linked prodrugs
WO2018035420A1 (en) 2016-08-18 2018-02-22 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
NZ751746A (en) 2016-09-29 2023-06-30 Ascendis Pharma Growth Disorders As Combination therapy with controlled-release cnp agonists
US20180194824A1 (en) 2016-12-14 2018-07-12 University Of Iowa Research Foundation Musclin peptides and methods of use thereof
WO2018139464A1 (ja) * 2017-01-24 2018-08-02 第一三共株式会社 低身長症治療剤
AU2018231832A1 (en) 2017-03-10 2019-08-08 Quiapeg Pharmaceuticals Ab Releasable conjugates
JP7126270B2 (ja) * 2017-03-22 2022-08-26 ファーマイン コーポレイション Ｎｐｒａアゴニスト、組成物およびその使用
JP2020512363A (ja) 2017-03-31 2020-04-23 アレクシオン ファーマシューティカルズ， インコーポレイテッド 成人及び青年における低ホスファターゼ症（ｈｐｐ）を治療する方法
JP2021519590A (ja) 2018-03-30 2021-08-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 糖タンパク質の製造
EP3553082A1 (en) 2018-04-12 2019-10-16 Bayer Aktiengesellschaft Brain natriuretic peptide engrafted antibodies
EP3553081A1 (en) 2018-04-12 2019-10-16 Bayer Aktiengesellschaft Atrial natriuretic peptide engrafted antibodies
EP3553079A1 (en) 2018-04-12 2019-10-16 Bayer Aktiengesellschaft C-type natriuretic peptide engrafted antibodies
WO2020033867A2 (en) 2018-08-10 2020-02-13 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
EP3849660A1 (en) 2018-09-12 2021-07-21 QuiaPEG Pharmaceuticals AB Releasable glp-1 conjugates
CN113423384B (zh) * 2019-02-11 2024-01-05 阿森迪斯药物生长障碍股份有限公司 Cnp缀合物的干燥药物制剂
BR112021024938A2 (pt) 2019-06-12 2022-01-25 Novartis Ag Anticorpos de receptor 1 de peptídeo natriurético e métodos de uso
US20220280647A1 (en) * 2019-08-12 2022-09-08 Biomarin Pharmaceutical Inc. Hydrophobic Peptide Salts for Extended Release Compositions
WO2021055497A1 (en) * 2019-09-16 2021-03-25 Biomarin Pharmaceutical Inc. Cnp variants and conjugates thereof
JP7796645B2 (ja) 2019-12-09 2026-01-09 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼポリペプチド及びその使用方法
AU2021288219A1 (en) * 2020-06-12 2023-02-02 Pharmain Corporation C-type natriuretic peptides and methods thereof in treating acute lung injury
IL302567A (en) * 2020-11-09 2023-07-01 Realta Life Sciences Inc Peptide formulations and methods of use
JP2023550784A (ja) * 2020-11-25 2023-12-05 プロリンクス エルエルシー Ｃ－ナトリウム利尿ペプチドの徐放性ヒドロゲルコンジュゲート
CA3173631A1 (en) 2021-02-12 2022-08-18 Walter C. Voegtli Alkaline phosphatase polypeptides and methods of use thereof
RU2763661C2 (ru) * 2021-03-31 2021-12-30 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) Способ терапии и профилактики прогрессирования хронической почечной недостаточности
MX2024000526A (es) 2021-07-09 2024-02-02 Biomarin Pharm Inc Variantes del peptido natriuretico tipo c para tratar la displasia esqueletica en ni?os.
WO2023108005A1 (en) 2021-12-07 2023-06-15 Biomarin Pharmaceutical Inc. C-type natriuretic peptide therapy of bone-related disorders
WO2023110758A1 (en) * 2021-12-13 2023-06-22 Ascendis Pharma Growth Disorders A/S Effective doses of cnp conjugates
WO2023117855A1 (en) * 2021-12-20 2023-06-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of analog of c-type natriuretic peptide for the treatment of fgfr-related bone repair and bone formation impairment
JP2025510608A (ja) * 2022-03-11 2025-04-15 アビラマックス・バイオファーマ・インコーポレイテッド 治療剤を発現させるための組成物および方法
CA3249311A1 (en) 2022-05-23 2023-11-30 Ascendis Pharma Growth Disorders A/S LIQUID PHARMACEUTICAL FORMULATIONS OF CNP COMPOUNDS
KR102866559B1 (ko) 2022-11-02 2025-10-02 노보 노르디스크 에이/에스 Cnp 화합물
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
EP4635974A1 (en) * 2022-12-12 2025-10-22 LG Household & Health Care Ltd. Cosmetic composition for skin improvement
WO2024194300A1 (en) 2023-03-20 2024-09-26 Ascendis Pharma Growth Disorders A/S Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia
TW202513806A (zh) 2023-06-07 2025-04-01 美商拜奧馬林製藥公司 高通量篩選與身材矮小相關之基因變異體
US12427185B2 (en) 2023-09-05 2025-09-30 E-Star Biotech, LLC Formulations of MANP and uses thereof
WO2025101863A1 (en) 2023-11-08 2025-05-15 Biomarin Pharmaceutical Inc. Cnp variants, conjugates and formulations thereof
WO2025222300A1 (en) * 2024-04-24 2025-10-30 Proteinqure Inc. Atrial natriuretic peptide constructs for targeted payload delivery to npr-c expressing cells
WO2026030743A1 (en) 2024-08-02 2026-02-05 Biomarin Pharmaceutical Inc. Treatment of short stature with cnp variants
CN119529033A (zh) * 2024-12-02 2025-02-28 中山大学 一种用于npr-b靶向的超长效多肽及其在骨骼系统病症中的应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69108830T2 (de) 1990-04-20 1995-09-14 Hisayuki Matsuo Neue im schwein vorkommende physiologisch aktive peptide.
JP2930380B2 (ja) 1990-07-13 1999-08-03 壽之 松尾 ブタ由来新規生理活性ペプチド（ｃｎｐ―５３）
JP3026351B2 (ja) 1990-07-13 2000-03-27 壽之 松尾 ブタｃｎｐ遺伝子及び前駆体蛋白
JP3026354B2 (ja) 1990-09-27 2000-03-27 壽之 松尾 ヒトｃｎｐ遺伝子及び前駆体蛋白
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
JP2809533B2 (ja) 1991-01-31 1998-10-08 壽之 松尾 Ｃｎｐ類似体ペプチド
AU6360394A (en) 1993-03-03 1994-09-26 Mayo Foundation For Medical Education And Research Vasonatrin peptide and analogs thereof
US5846932A (en) 1993-11-12 1998-12-08 Genentech, Inc. Receptor specific atrial natriuretic peptides
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
HU228446B1 (en) 1996-04-12 2013-03-28 Warner Lambert Co Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof
WO1999007701A1 (en) 1997-08-05 1999-02-18 Sugen, Inc. Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
US6136040A (en) 1998-03-05 2000-10-24 Washington University Animal model with disrupted FGF-9 gene
IL125958A0 (en) 1998-08-27 1999-04-11 Yeda Res & Dev Animal model for fibroblast growth factor receptor associated chondrodysplasia
WO2000061631A1 (en) 1999-04-12 2000-10-19 Astrazeneca Ab Modified pentapeptide antagonists of the atrial natriuretic peptide clearance receptor
US6849714B1 (en) * 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6407211B1 (en) * 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
US20040082765A1 (en) 2000-10-16 2004-04-29 Teruo Nakamura Peg-modified erythropoietin
JP2002178279A (ja) 2000-12-12 2002-06-25 Ulvac Japan Ltd 基板搬送方法
IL142118A0 (en) 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
BRPI0203172B8 (pt) 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
US20040077537A1 (en) * 2002-03-18 2004-04-22 Schreiner George F. Method for treating congestive heart failure
US6861236B2 (en) * 2002-05-24 2005-03-01 Applied Nanosystems B.V. Export and modification of (poly)peptides in the lantibiotic way
WO2004043396A2 (en) * 2002-11-09 2004-05-27 Nobex Corporation Modified carbamate-containing prodrugs and methods of synthesizing same
US7648962B2 (en) 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
EP1569683B1 (en) 2002-11-26 2010-03-03 Biocon Limited Modified natriuretic compounds, conjugates, and uses thereof
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DE602004030342D1 (de) 2003-06-17 2011-01-13 Otago Innovation Ltd Beurteilung des skelettwachstums unter verwendung von messungen von nt-cnp-peptiden
EP1525890A1 (en) 2003-10-02 2005-04-27 Complex Biosystems GmbH Protein-Proteophore complexes
JP4950022B2 (ja) 2004-03-23 2012-06-13 コンプレックス バイオシステムズ ゲーエムベーハー 自壊性リンカーを有する高分子プロドラッグ
EP3620530A1 (en) 2004-03-31 2020-03-11 Kazuwa Nakao Composition for increasing body height
JP4825667B2 (ja) * 2004-03-31 2011-11-30 一和 中尾 関節炎症治療剤又は予防剤
JP2005292718A (ja) 2004-04-05 2005-10-20 Furukawa Electric Co Ltd:The 光導波路、光導波路モジュールおよび光導波路の作成方法
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
ATE496060T1 (de) * 2004-07-15 2011-02-15 Univ Queensland Proteinartige verbindungen und anwendungen davon
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
US20100310561A1 (en) 2007-06-06 2010-12-09 Boehringer Ingelheim International Gmbh Natriuretic fusion proteins
AU2008279379B2 (en) * 2007-07-20 2016-03-24 Mayo Foundation For Medical Education And Research Natriuretic polypeptides
CA2699169A1 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Therapeutic uses of intermedin 47 and 53 peptides
AU2008326327A1 (en) * 2007-11-21 2009-05-28 Biomarin Pharmaceutical Inc. Variants of C-type natriuretic peptide
WO2009086166A1 (en) 2007-12-19 2009-07-09 Ekr Therapeutics, Inc. Room temperature stable, lyophilized natriuretic peptide formulations
CN101980725B (zh) 2008-02-01 2013-06-12 阿森迪斯药物股份有限公司 包含可自裂解的连接体的前药
HRP20160303T1 (hr) * 2008-05-23 2016-04-22 Daiichi Sankyo Company, Limited Peptid koji je sposoban produljiti vrijeme polu-života pogodnih peptida u plazmi
EP2334334A1 (en) 2008-09-19 2011-06-22 Nektar Therapeutics Polymer conjugates of nesiritide peptides
PE20120792A1 (es) 2009-05-20 2012-07-27 Biomarin Pharm Inc Variantes de peptidos natriureticos de tipo c
US9062094B2 (en) 2010-01-22 2015-06-23 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs

Also Published As

Publication number Publication date
EP4523749A2 (en) 2025-03-19
TW201100092A (en) 2011-01-01
AR078044A1 (es) 2011-10-12
HUE057174T2 (hu) 2022-04-28
HRP20161739T1 (hr) 2017-03-10
BR122019026832B1 (pt) 2021-08-24
BRPI1012783B1 (pt) 2021-09-21
KR20190119179A (ko) 2019-10-21
US8598121B2 (en) 2013-12-03
EP4523749A3 (en) 2025-05-07
NL301162I2 (nl) 2026-02-12
KR20230142644A (ko) 2023-10-11
NO2022003I1 (no) 2024-08-05
AU2010249802A1 (en) 2011-10-13
US20170051033A1 (en) 2017-02-23
DK3175863T3 (da) 2022-02-07
EP2432489A2 (en) 2012-03-28
KR102033680B1 (ko) 2019-10-18
RU2011152007A (ru) 2013-06-27
EP3175863B1 (en) 2021-12-01
EP4591934A2 (en) 2025-07-30
HUE032582T2 (en) 2017-09-28
IL215287A (en) 2015-04-30
IL215287A0 (en) 2011-11-30
USRE48267E1 (en) 2020-10-20
BRPI1012783A2 (pt) 2018-01-16
EP2432489B1 (en) 2016-10-05
US20120316114A1 (en) 2012-12-13
PT3175863T (pt) 2022-01-20
EP4029512A1 (en) 2022-07-20
KR102225470B1 (ko) 2021-03-10
LUC00248I2 (pl) 2025-03-04
EP3175863A1 (en) 2017-06-07
CL2011002430A1 (es) 2012-02-17
US20160256553A1 (en) 2016-09-08
HRP20220057T1 (hr) 2022-04-15
US8198242B2 (en) 2012-06-12
HK1168279A1 (zh) 2012-12-28
PT2432489T (pt) 2016-12-07
USRE46707E1 (en) 2018-02-13
PE20120792A1 (es) 2012-07-27
HUS2200004I1 (hu) 2022-05-28
JP2012527244A (ja) 2012-11-08
KR20180021233A (ko) 2018-02-28
KR101831923B1 (ko) 2018-02-26
ES2608457T3 (es) 2017-04-11
MX2011012277A (es) 2011-12-12
RU2573911C2 (ru) 2016-01-27
WO2010135541A2 (en) 2010-11-25
FR22C1004I1 (fr) 2022-03-11
WO2010135541A3 (en) 2011-01-20
KR20120034660A (ko) 2012-04-12
FR22C1004I2 (fr) 2023-01-13
AU2010249802B2 (en) 2017-06-08
TWI471137B (zh) 2015-02-01
ZA201107087B (en) 2012-12-27
JP5718909B2 (ja) 2015-05-13
CA2758581A1 (en) 2010-11-25
FIC20220003I1 (fi) 2022-01-19
CN102481330B (zh) 2014-12-10
PL2432489T3 (pl) 2017-05-31
US20100297021A1 (en) 2010-11-25
EP2432489A4 (en) 2013-04-03
CN102481330A (zh) 2012-05-30
ES2904360T3 (es) 2022-04-04
CA2758581C (en) 2022-06-14
DK2432489T3 (en) 2017-01-16
KR20210027537A (ko) 2021-03-10

Similar Documents

Publication Publication Date Title
FR22C1004I2 (fr) Variants du peptide natriuretique de type c
FIC20220051I1 (fi) Olipudaasi alfa
TWI367213B (en) Variants of c-type natriuretic peptide
IL249285A0 (en) Transaminase polypeptides
DK2171053T3 (da) Natriuretiske polypeptider
DK2225988T3 (da) Dispenserhus
EP2406399A4 (en) MIRAC PROTEINS
DK3320979T3 (da) Dispenser
EP2437770A4 (en) ANTIMICROBIAL PEPTIDES
BRPI1010661A2 (pt) peptídeo
ATE546999T1 (de) Feldspritze
DE112010000691A5 (de) Chromatographievorrichtung
EP2403315A4 (en) LIGHT-EMITTING ITEM
DOP2011000348A (es) Construcciones casb7439
EP2512583C0 (en) SHEATH
BRPI1012729A2 (pt) dispensador
IT1397007B1 (it) Dispenser
GB0908515D0 (en) Peptide
IT1395137B1 (it) Nuovi peptidi antipatogeni
EP2280988A4 (en) ANGIOGENIC PEPTIDE
ZA201203722B (en) Peptide
BR112013009679A2 (pt) peptídeo
FR2943455B1 (fr) Declencheur magnetothermique
FIU20090437U0 (fi) Pilkkionki
UA19575S (uk) Обприскувач